Lipstatin: A Comprehensive Reference Article
1. Identity: Chemical Name, Natural Source, and Common Forms
1.1 Classification and Nomenclature
Lipstatin is a potent, irreversible inhibitor of pancreatic lipase. It is a natural product that was first isolated from the actinobacterium Streptomyces toxytricini. More precisely, lipstatin is a fatty acid β-lactone produced by a strain of Streptomyces toxytricini and it inhibits the activity of pancreatic lipases.
The structure of lipstatin, produced by Streptomyces toxytricini, was determined as (2S,3S,5S,7Z,10Z)-5-[(S)-2-formamido-4-methylpentanoyloxy]-2-hexyl-3-hydroxy-7,10-hexadecadienoic lactone by spectroscopic and chemical methods.
Lipstatin is composed of a 2-hexyl-3,5-dihydroxy-7,10-hexadecadienoic-β-lactone 22-carbon backbone from the fatty acid synthesis pathway, with an N-formyl-L-leucine group ester-linked to the 5-hydroxyl group of the backbone. The ultimate biosynthetic constituents of lipstatin are linoleic acid, octanoic acid, and L-leucine.
Structurally, it contains one β-lactone ring and two aliphatic side chains comprising 6 and 13 carbon atoms. The 13-carbon side chain contains two isolated double bonds and one hydroxyl group, which is esterified to N-formyl-L-leucine.
1.2 Structural Relationship to Esterastin
Structurally, lipstatin is closely related to the known esterase inhibitor esterastin. It contains an N-formyl-L-leucine side chain instead of the N-acetyl-L-asparagine found in esterastin.
1.3 Other Microbial Producers
Lipstatin is one of the most critical antiobesity compounds, produced from Streptomyces toxytricini and S. virginiae as a secondary metabolite.
1.4 Relationship to Orlistat (Tetrahydrolipstatin)
The popular antiobesity drug orlistat (trade names Xenical and Alli) is a saturated derivative of lipstatin. Tetrahydrolipstatin, more commonly known as orlistat, is a saturated derivative produced by hydrogenation. It was developed in 1983 by Hoffmann-La Roche and is a more simple and stable compound than lipstatin. For that reason, orlistat was chosen over lipstatin for development as an anti-obesity drug.
Orlistat is poorly absorbed (less than 2%) and is mostly excreted in unchanged form through the faeces. Because orlistat is the commercially developed and clinically deployed derivative, the scientific and clinical evidence base discussed throughout this article applies to orlistat as the pharmacologically active form descended from lipstatin.
1.5 Forms and Preparations
Lipstatin itself is not formulated as a commercial pharmaceutical or dietary supplement in its native, unsaturated state. It serves as the natural precursor from which orlistat (tetrahydrolipstatin) is derived. Lipstatin is a pancreatic lipase inhibitor produced by Streptomyces toxytricini that is used to combat obesity and diabetes; it interferes with the gastrointestinal absorption of fat. The commercial product is tetrahydrolipstatin, which is also known as orlistat.
In research settings, lipstatin is obtained by submerged fermentation of Streptomyces strains. Lipstatin becomes inactive at alkaline pH due to the opening of the β-lactone ring. This instability under alkaline conditions is among the key reasons that the hydrogenated derivative, orlistat, was selected for pharmaceutical development over lipstatin itself. Orlistat is commercially available as 120 mg prescription capsules (Xenical) and 60 mg over-the-counter capsules (Alli).
2. Discovery and Historical Background
2.1 Scientific Discovery
Pancreatic lipase inhibitor was originally discovered and isolated from fermented broth of the Streptomyces toxytricini bacterium in 1981 and named lipstatin. The foundational characterization of this compound was published in two landmark papers in The Journal of Antibiotics in August 1987 by researchers at F. Hoffmann-La Roche & Co., Ltd., in Basel, Switzerland.
The research group of E. K. Weibel, P. Hadvary, E. Hochuli, E. Kupfer, and H. Lengsfeld, at the Central Research Units of F. Hoffmann-La Roche & Co., Ltd., Basel, Switzerland, described lipstatin as a new and very potent inhibitor of pancreatic lipase (the key enzyme of intestinal fat digestion), isolated from Streptomyces toxytricini. They established that lipstatin contains a beta-lactone structure that probably accounts for the irreversible lipase inhibition, that the IC50 of lipstatin for pancreatic lipase is 0.14 microM, and that in mice triolein absorption was dose-dependently inhibited by lipstatin, whereas oleic acid was absorbed normally.
Orlistat was developed in 1983 by Hoffmann-La Roche and, as a more simple and stable compound than lipstatin, was chosen over lipstatin for development as an anti-obesity drug. Orlistat was approved by the FDA for prescription sale in 1999 and over-the-counter sale in 2007, and remains the only approved therapy in Europe for long-term management of obesity.
2.2 No Traditional Ethnobotanical or Ethnomedicinal Use
Lipstatin has no documented traditional or historical use by any human culture. It is a natural product of microbial fermentation — a secondary metabolite of soil-dwelling actinobacteria — and has no known application in traditional medicine, herbal systems, or folk pharmacopoeias prior to its scientific discovery in the 1980s. Lipstatin is a natural product of microbial origin, and orlistat is the result of a hydrogenation of lipstatin. Its history is therefore entirely a product of modern pharmaceutical and biochemical research, without roots in any traditional healing tradition. Any suggestion to the contrary is not supported by the peer-reviewed scientific literature.
3. Biosynthesis and Key Constituents
3.1 Biosynthetic Origin
Lipstatin is composed of a polyketide backbone made from 3-hydroxytetradeca-5,8-dienoic acid and hexylmalonic acid, and N-formylleucine.
The lipstatin backbone is formed via Claisen condensation of two fatty acid precursors, octanoic acid and tetradeca-5,8-dienoic acid. Specifically, the carbon skeleton of the lipstatin molecule is biosynthesized via Claisen condensation of two fatty acid precursors: an 8-carbon unit (octanoic acid) and a 14-carbon unit (tetradeca-5,8-dienoic acid).
The labeling pattern of the β-lactone moiety can be explained by Claisen condensation of octanoyl-CoA with 3-hydroxy-5,8-tetradecanoyl-CoA obtained by β-oxidation of linoleic acid, as opposed to polyketide-type biosynthesis from low-molecular-weight fragments.
3.2 The Biosynthetic Gene Cluster
In the 62 kb fragment of the pccB gene locus of Streptomyces toxytricini producing the pancreatic inhibitor lipstatin, three distinct subunit genes of a presumable propionyl-CoA carboxylase (PCCase) complex, assumed to be one of the acyl-CoA carboxylases (ACCase) responsible for secondary metabolism, were identified along with a gene for biotin protein ligase (Bpl). This enzyme complex is thought to play a main role in the production of methylmalonyl-CoA from propionyl-CoA, which is a precursor of secondary polyketide biosynthesis.
3.3 Structural Key Features
The single most pharmacologically critical structural feature of lipstatin is its β-lactone ring. It contains a beta-lactone structure that is likely responsible for irreversibly binding to the active site of lipase. The unsaturated character of lipstatin (containing two double bonds in the C13 chain) distinguishes it from its hydrogenated pharmaceutical derivative, orlistat, and contributes to the compound's relative chemical instability, particularly at non-acidic pH values.
4. Mechanisms of Action
4.1 Pancreatic and Gastric Lipase Inhibition
Gastric and pancreatic lipases are enzymes that play a pivotal role in the digestion of dietary fat. Orlistat, a semisynthetic derivative of lipstatin, is a potent and selective inhibitor of these enzymes, with little or no activity against amylase, trypsin, chymotrypsin, and phospholipases. It exerts its effect within the gastrointestinal (GI) tract. Orlistat acts by binding covalently to the serine residue of the active site of gastric and pancreatic lipases. When administered with fat-containing foods, orlistat partially inhibits hydrolysis of triglycerides, thus reducing the subsequent absorption of monoacylglycerides and free fatty acids.
It is an active site-directed inhibitor that reacts with the nucleophilic serine residue from the catalytic triad of pancreatic lipase.
4.2 Irreversible Binding and Selectivity
Lipstatin is a potent and irreversible inhibitor of pancreatic lipase. The IC50 of lipstatin for pancreatic lipase is 0.14 microM. In mice, triolein absorption was dose-dependently inhibited by lipstatin, whereas oleic acid was absorbed normally. Other pancreatic enzymes, such as phospholipase A2 and trypsin, were not inhibited even at an inhibitor concentration of 200 microM.
Orlistat (as the pharmacologically active derivative of lipstatin) is not selective for GI lipases, but inhibits a broad range of lipases including gastric, pancreatic, lipoprotein, hepatic, and hormone-sensitive lipases.
4.3 Net Effect on Fat Absorption
The inactivated enzyme is thus unavailable to hydrolyse dietary fat, in the form of triglycerides, into absorbable free fatty acids and monoglycerides. This allows about 30% of the fat ingested in a meal to pass through the gut undigested. As a result, the body cannot use this dietary fat for energy or convert it into fat tissue, which helps weight reduction.
Studies measuring actual inhibition in healthy human volunteers have confirmed these effects. Orlistat was found to be a powerful gastric lipase inhibitor, achieving 46.6–91.4% enzyme inhibition and thus greatly reducing gastric lipolysis of solid and liquid meals (11–33% of respective controls). Gastric lipase inhibition by orlistat was extremely fast (half-inhibition time less than 1 minute). Human pancreatic lipase inhibition was found to be high (51.2–82.6%), regardless of the meal.
4.4 Fatty Acid Synthase Inhibition
Orlistat is also a potent thioesterase inhibitor and therefore inhibits fatty acid synthase (FAS). Since FAS is essential for tumor cells, for their growth and survival, and is upregulated and overexpressed in a variety of tumors, scientists have high expectations for FAS as an oncology drug target. This mechanism remains an area of active research interest, with evidence so far primarily at the cellular and preclinical level.
5. Scientific Evidence by Area of Use
5.1 Obesity and Body Weight Reduction
Evidence Summary
The clinical evidence base for lipstatin's pharmacologically active derivative, orlistat, is among the largest assembled for any anti-obesity medication. In several trials lasting up to two years, orlistat was more effective than diet alone for weight reduction and maintenance of lost weight. Orlistat treatment also results in modest improvements in total cholesterol, low-density lipoprotein, blood pressure, and fasting glucose and insulin concentrations.
Key Randomized Controlled Trials and Systematic Reviews
Most trials showed greater weight loss and better weight maintenance with orlistat compared to placebo at all endpoints, with statistically significant differences for both outcomes. Orlistat 120 mg three times daily was the optimum regimen in terms of weight loss. Most trials showed significant improvement in at least some lipid concentration parameters, and, in three RCTs, orlistat produced statistically significant reductions in blood pressure relative to placebo.
A systematic review and meta-analysis published in BJGP Open (2025), focusing specifically on patients with type 2 diabetes or those at high risk of it, found: Thirty RCTs compared orlistat with a comparator, in conjunction with a weight-loss diet. All trials showed statistically significant (P<0.05) greater weight loss for the orlistat group than controls. A meta-analysis of 22 studies (n = 5,921) showed that the overall weight loss for the orlistat group was a mean of 2.40 kg (95% CI = 2.08 to 2.72) greater than in controls.
A 2025 systematic review and network meta-analysis in Nature Medicine identified 56 clinical trials including 22 orlistat trials, enrolling 60,307 patients total. It reported that tirzepatide and semaglutide are the most effective obesity management medications in reducing body weight and obesity-related complications, placing orlistat's magnitude of weight reduction below that of the newer GLP-1 receptor agonist class.
Strength of Evidence
Evidence is strong and consistent across multiple large RCTs and systematic reviews. The effect size — approximately 2–3 kg greater weight loss than placebo when used adjunctively with diet — is statistically robust but clinically modest compared to newer agents. A pattern of poor adherence and persistence with anti-obesity medications including orlistat has been observed across real-world studies.
5.2 Type 2 Diabetes Prevention
The XENDOS Trial
The XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study was a 4-year (1997–2002), double-blind, randomized, placebo-controlled prospective analysis conducted with 22 medical centres in Sweden. The primary purpose of the study was to determine long-term effects of orlistat on the reduction of progression to type 2 diabetes (T2DM) when combined with lifestyle changes. The study also aimed to determine the weight loss effect of orlistat treatment on metabolic abnormalities while evaluating cardiovascular risks.
In this 4-year, double-blind, prospective study, 3,305 patients were randomized to lifestyle changes plus either orlistat 120 mg or placebo, three times daily. Participants had a BMI ≥ 30 kg/m² and normal (79%) or impaired (21%) glucose tolerance (IGT).
After 4 years' treatment, the cumulative incidence of diabetes was 9.0% with placebo and 6.2% with orlistat, corresponding to a risk reduction of 37.3% (P = 0.0032). Exploratory analyses indicated that the preventive effect was explained by the difference in subjects with IGT. Mean weight loss after 4 years was significantly greater with orlistat (5.8 vs. 3.0 kg with placebo; P < 0.001) and similar between orlistat recipients with impaired or normal glucose tolerance at baseline.
Compared with lifestyle changes alone, orlistat plus lifestyle changes resulted in a greater reduction in the incidence of type 2 diabetes over 4 years and produced greater weight loss in a clinically representative obese population. The difference in diabetes incidence was detectable only in the IGT subgroup; weight loss was similar in subjects with IGT or NGT.
Evidence in Established Type 2 Diabetes
In obese patients with type 2 diabetes, orlistat resulted in a significantly greater weight loss at 1 year compared with placebo, and some parameters of glycaemic control and lipid concentration also showed significantly greater improvements compared with placebo. Orlistat also showed significant decreases in glycaemic control parameters (FPG and/or HbA1c levels), reduced insulin resistance, and improved insulin sensitivity.
Strength of Evidence
Evidence for diabetes risk reduction is strong within the context of IGT at baseline, based on the landmark XENDOS trial. The degree to which any benefit is independent of weight loss per se (rather than being a consequence of it) remains an area of scientific discussion.
5.3 Lipid Parameters and Cardiovascular Risk Factors
Orlistat blocks fat absorption, which can lower cholesterol levels. In the XENDOS trial, orlistat-treated patients had an average decrease in LDL of 12.8% compared to 5.1% with placebo.
A Cochrane meta-analysis evaluating lipid changes in orlistat weight-loss trials lasting one year or longer reported: Total cholesterol decreased by an average of 12 mg/dL when compared to placebo (13 trials); LDL cholesterol decreased by an average of 10 mg/dL when compared to placebo (13 trials); HDL cholesterol decreased by an average of 1.1 mg/dL when compared to placebo (11 trials); and triglyceride levels did not change significantly (11 trials).
Orlistat improved cardiovascular risk profiles by lowering blood triglyceride and LDL-cholesterol levels and raising HDL-cholesterol levels in patients who were noticeably obese. Orlistat-induced weight loss also appears to have beneficial effects on blood pressure.
Strength of Evidence
Evidence for improvement in lipid parameters is consistent across multiple RCTs. These effects are largely attributed to reduced dietary fat absorption and consequent weight loss, rather than a direct pharmacological action on lipid metabolism. Long-term cardiovascular event data are limited.
5.4 Fatty Acid Synthase Inhibition and Oncology (Preclinical)
Orlistat (the lipstatin derivative) is also a potent thioesterase inhibitor and therefore inhibits fatty acid synthase (FAS). Since FAS is essential for tumor cells, for their growth and survival, and is upregulated and overexpressed in a variety of tumors, scientists have proposed FAS as a potential oncology drug target. This application of lipstatin-class compounds remains at the preclinical stage, and there are no published RCTs in humans for any oncological indication using lipstatin or orlistat. Evidence should currently be characterized as preliminary and confined to laboratory and animal studies.
6. Body Systems and Health Areas of Association
Based on established mechanisms and clinical evidence, lipstatin (acting through its derivative orlistat) is associated with the following body systems and health domains:
- Gastrointestinal system: Primary site of action. Lipstatin-class compounds act entirely within the lumen of the gastrointestinal tract — stomach and small intestine — inhibiting fat digestion at the luminal surface. Orlistat is the only anti-obesity medicine that does not act on the central nervous system or enter the bloodstream.
- Adipose tissue and body weight regulation: By reducing dietary fat absorption by approximately 30%, lipstatin-class compounds reduce the energy available for deposition as adipose tissue, contributing to weight loss.
- Endocrine/metabolic system: Orlistat showed significant decreases in glycaemic control parameters (FPG and/or HbA1c levels), reduced insulin resistance, and improved insulin sensitivity in patients with type 2 diabetes or at high risk.
- Cardiovascular system: Through secondary effects of fat malabsorption and weight loss, improvements in LDL-cholesterol, total cholesterol, and blood pressure have been documented in clinical trials.
- Hepatic/biliary system: Orlistat has documented interactions with bile acid metabolism and has been studied in non-alcoholic fatty liver disease, where the effects of orlistat on non-alcoholic fatty liver disease are beneficial.
- Renal system: Fat malabsorption increases oxalate absorption, creating a risk of calcium oxalate nephrolithiasis. Caution should be exercised when prescribing orlistat to patients with a history of hyperoxaluria or calcium oxalate nephrolithiasis.
- Thyroid system: Clinical interaction with levothyroxine has been documented (see Section 8).
7. Dosage Forms and Dosages Reported in Studies
Lipstatin itself has not been studied in humans in clinical trials; all dosage data refer to orlistat (tetrahydrolipstatin), the pharmacologically active, commercially developed derivative.
- 120 mg three times daily: This was identified as the optimum regimen for weight loss in clinical trials of orlistat.
- 120 mg three times daily was the dose used in the landmark 4-year XENDOS randomized controlled trial (n = 3,305 participants).
- The usual dose of Xenical (prescription orlistat) is one 120 mg capsule taken with each of the three main meals per day.
- 60 mg three times daily: Orlistat was FDA-approved for over-the-counter use at this dose for obesity.
- In the XENDOS trial, at year one, mean weight loss was 10.6 kg with orlistat 120 mg three times daily versus 6.2 kg with placebo (P < 0.001). At four years, orlistat maintained a 5.8 kg superiority over placebo.
- At the recommended therapeutic dosage of 120 mg three times a day, orlistat inhibits dietary fat absorption by approximately 30%.
- Regarding systemic absorption: approximately 97% of the administered dose was excreted in feces, and 83% of that was unchanged orlistat.
8. Safety Considerations and Drug Interactions
8.1 Gastrointestinal Adverse Effects
Orlistat is minimally, if at all, absorbed, and its side effects are largely due to its effect on fat absorption including abdominal discomfort, bloating, gaseousness, diarrhea, fecal leakage, and steatorrhea (oily stools and fat-soluble vitamin malabsorption).
Use of orlistat may cause mild-to-moderate gastrointestinal adverse effects in 10%–51% of patients. More specifically, the use of orlistat has been associated with several mild-to-moderate gastrointestinal adverse effects, such as oily stools, diarrhoea, abdominal pain, and faecal spotting. Symptoms are particularly prominent if orlistat is given before a high-fat meal and they tend to lessen with more prolonged therapy. These adverse effects can be minimized by following a hypocaloric and low-fat diet with less than 30% of the calories from fats.
8.2 Fat-Soluble Vitamin Malabsorption
Treatment with orlistat may potentially impair the absorption of fat-soluble vitamins (A, D, E, and K). The vast majority of patients receiving up to four full years of treatment with orlistat in clinical studies had vitamin A, D, E, K, and beta-carotene levels that stayed within normal range.
The deficiencies are most notable with vitamins D, E, and beta-carotene. Since orlistat reduces the absorption of fat-soluble vitamins, patients should take multivitamin supplements (containing fat-soluble vitamins) daily. Administration of multivitamin supplements should be at a gap of more than 2 hours after the orlistat administration.
8.3 Hepatic Safety
A few cases of serious hepatic adverse effects (cholelithiasis, cholestatic hepatitis, and subacute liver failure) have been reported. In August 2009, the FDA reported that it was conducting an ongoing safety review of orlistat prompted by reports of adverse hepatic-related effects. In May 2010, the FDA's completed safety review of the available data identified 13 cases of severe liver injury reported in orlistat-treated patients; 2 resulted in death and 3 resulted in liver transplantation. The FDA stated that a causal relationship to orlistat cannot be established at this time.
This may provide some evidence of an adverse effect of orlistat on hepatic function but does not provide evidence of serious hepatotoxicity. It was noted that evidence from epidemiological studies suggests that obesity per se may be associated with an increased risk of liver disease.
8.4 Renal Considerations
Potential risks include lowered absorption of fat-soluble vitamins, potential liver injury, increases in urinary oxalate, and cholelithiasis. Orlistat is considered safe for use in patients with renal impairment. However, the risk of hyperoxaluria and oxalate nephropathy warrants caution in at-risk patients.
8.5 Drug Interactions
Orlistat may interact with concomitant drugs including cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, and antiretroviral drugs.
- Cyclosporine: Data from a drug interaction study indicate a reduction in cyclosporine plasma levels when orlistat was co-administered with cyclosporine. Therefore, orlistat and cyclosporine should not be simultaneously co-administered. To reduce the chance of a drug–drug interaction, cyclosporine should be taken at least 3 hours before or after orlistat in patients taking both drugs.
- Warfarin and anticoagulants: Using orlistat and warfarin can result in prolonged prothrombin time and INR because orlistat reduces the absorption of vitamin K. Therefore, coagulation parameters require monitoring.
- Levothyroxine: Patients treated concomitantly with orlistat and levothyroxine should be monitored for changes in thyroid function. Clinicians should advise patients to take levothyroxine and orlistat at least 4 hours apart.
- Amiodarone: A reduction in exposure to amiodarone was observed when orlistat was co-administered.
- Antiepileptic drugs: Convulsions have been reported in patients taking orlistat with antiepileptic drugs. Patients should be monitored for possible changes in frequency or severity of convulsions.
8.6 Contraindications
The use of orlistat is contraindicated in patients with chronic malabsorption syndrome or cholestasis. Orlistat can worsen malabsorption in these conditions by reversibly inhibiting lipases that are necessary for the hydrolysis of triglycerides into absorbable free fatty acids and monoglycerides.
Caution is advised when prescribing orlistat to patients with obstructed bile ducts and abnormal liver function tests.
8.7 Special Populations
The safety of orlistat is not established in the paediatric population under the age of 12 years. However, it is deemed to be safe in the paediatric population aged 12–16 years. Adverse effects in children were similar to those found in adults.
8.8 Mineral Balance
No effect has been observed on calcium, phosphorus, magnesium, iron, copper, or zinc balance, or on bone biomarkers.
9. Context Within Microbial Natural Products
Lipstatin belongs to an important class of bioactive microbial secondary metabolites — the β-lactone lipase inhibitors. Lipase inhibitors from microbial sources can be divided into two classes based on their structure: those that have a β-lactone ring, including lipstatin, valilactone, percyquinin, panclicins A–E, ebelactone A and B, vibralactone, and esterastin; and those that do not have a β-lactone ring.
A wide variety of natural products have been used as pancreatic lipase inhibitors, originating from plants and metabolites of microorganisms. These include lipstatin, panclicins, saponins, polyphenols, flavonoids, caffeine, chitin, and chitosan. Among this class, lipstatin stands out as the only microbial natural product to have directly yielded an FDA-approved pharmaceutical agent for obesity treatment.
As a subject of ongoing fermentation optimization research, strain improvement to enhance the production of lipstatin has been carried out by different doses of gamma radiation and precursors (linoleic acid, oleic acid, and L-leucine). Screening showed that the highest yield of lipstatin (4.58 mg/g) was produced by a mutant designated as SRN 7.
References
- Weibel EK, Hadvary P, Hochuli E, Kupfer E, Lengsfeld H. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity. J Antibiot. 1987;40(8):1081–1085. PubMed
- Hochuli E, Kupfer E, Maurer R, Meister W, Mercadal Y, Schmidt K. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. II. Chemistry and structure elucidation. J Antibiot. 1987;40(8):1086–1091. PubMed
- Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord. 1997;21(Suppl 3):S12–23. PubMed
- Enhanced production of lipstatin from mutant of Streptomyces toxytricini and fed-batch strategies under submerged fermentation. PMC / NIH.
- Lipstatin – an overview. ScienceDirect Topics (Neuroscience).
- Lipstatin – an overview. ScienceDirect Topics (Medicine and Dentistry).
- Streptomyces toxytricini – an overview. ScienceDirect Topics (Agricultural and Biological Sciences).
- Lipstatin. Wikipedia.
- Discovery and development of gastrointestinal lipase inhibitors. Wikipedia.
- Microbial drug discovery: 80 years of progress. PMC / NIH.
- Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy. 2000;20(3):270–279. Wiley Online Library.
- O'Meara S, et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. PubMed.
- Efficacy of orlistat in type 2 diabetes: a systematic review and meta-analysis. BJGP Open. 2025.
- Efficacy of orlistat in type 2 diabetes: a systematic review and meta-analysis. PMC / NIH. 2025.
- Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. Diabetes Care. 2004;27(1):155–161.
- XENical in the prevention of diabetes in obese subjects (XENDOS) study. PubMed.
- Weir MA, et al. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Safety. 2008;31(1):5–16. Springer.
- Orlistat. LiverTox®. NCBI Bookshelf / NIH.
- Orlistat. StatPearls. NCBI Bookshelf / NIH.
- Xenical (orlistat) prescribing information. FDA. 2022.
- Orlistat capsule prescribing information. DailyMed / NIH.
- Assessment report for orlistat-containing medicinal products. European Medicines Agency (EMA).
- Inhibition of gastrointestinal lipolysis by orlistat during digestion of test meals in healthy volunteers. American Journal of Physiology – Gastrointestinal and Liver Physiology.
- The role of acyl-coenzyme A carboxylase complex in lipstatin biosynthesis of Streptomyces toxytricini. Applied Microbiology and Biotechnology. Springer.
- A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nature Medicine. 2025.
- Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review. PMC / NIH.
Volver